AR079774A1 - Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo - Google Patents

Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo

Info

Publication number
AR079774A1
AR079774A1 ARP100102570A ARP100102570A AR079774A1 AR 079774 A1 AR079774 A1 AR 079774A1 AR P100102570 A ARP100102570 A AR P100102570A AR P100102570 A ARP100102570 A AR P100102570A AR 079774 A1 AR079774 A1 AR 079774A1
Authority
AR
Argentina
Prior art keywords
ftalazinone
composite
pharmaceutical composition
same
crystaline form
Prior art date
Application number
ARP100102570A
Other languages
English (en)
Inventor
Neil Hawkins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR079774A1 publication Critical patent/AR079774A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

4-(4-fluoro-3-(4-metoxipiperidin-1-carbonil)bencil)ftalazin-1(2H)-ona como la forma cristalina C. Reivindicacion 4: El compuesto de la reivindicacion 1, caracterizado porque tiene al menos cuatro de los siguientes picos característicos en una XRD en polvo usando radiacion de CuKa: 19,3, 18,5, 18,9, 22,8, 10,5, 23,2°. Reivindicacion 7: Una composicion farmacologica caracterizada porque comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 6 y un vehículo o diluyente aceptable para uso farmacéutico. Reivindicacion 10: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 6 caracterizado porque es en la preparacion de un medicamento para inhibir la actividad de PARP.
ARP100102570A 2009-07-15 2010-07-15 Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo AR079774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22582509P 2009-07-15 2009-07-15

Publications (1)

Publication Number Publication Date
AR079774A1 true AR079774A1 (es) 2012-02-22

Family

ID=42732059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102570A AR079774A1 (es) 2009-07-15 2010-07-15 Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo

Country Status (5)

Country Link
US (1) US20110015393A1 (es)
AR (1) AR079774A1 (es)
TW (1) TW201114756A (es)
UY (1) UY32790A (es)
WO (1) WO2011007145A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222584A1 (en) * 2009-02-06 2010-09-02 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
CN109223787A (zh) * 2018-10-04 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种喜树碱和新型酞嗪酮类化合物联合用药物组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) * 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
ATE60598T1 (de) * 1985-11-11 1991-02-15 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
ATE209660T1 (de) 1994-08-12 2001-12-15 Myriad Genetics Inc 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen
PT705903E (pt) 1994-08-12 2001-11-30 Myriad Genetics Inc Mutacoes no gene de susceptibilidade para o cancro da mama e do ovario ligado a 17q
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
CA2205757C (en) * 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6426415B1 (en) * 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU1407399A (en) * 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6476048B1 (en) * 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB2415430B (en) * 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
CN101484421A (zh) * 2006-06-15 2009-07-15 库多斯药物有限公司 作为parp抑制剂的2-氧基苯甲酰胺衍生物
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona

Also Published As

Publication number Publication date
TW201114756A (en) 2011-05-01
UY32790A (es) 2011-02-28
US20110015393A1 (en) 2011-01-20
WO2011007145A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
PH12014502540B1 (en) Benzimidazole-proline derivatives
AR096759A1 (es) Formas sólidas de un inhibidor de quinasa macrocíclica
AR090151A1 (es) Compuestos inhibidores de raf
MX2014010494A (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
UY33286A (es) Derivados de triazina disustituidos farmaceuticamente activos
PH12016501258A1 (en) Cortistatin analogues and syntheses and uses thereof
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
PH12015500764B1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
CU20090225A7 (es) 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal
DOP2011000260A (es) Pirimidinas fusionadas
UY35355A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONIS TA DEL RECEPTOR ß2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M3.
PE20210153A1 (es) Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2
MX342440B (es) Derivados fluorados de aminotriazol.
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
WO2015085909A8 (zh) 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12016500985A1 (en) Use of benzimidazole-proline derivatives
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
UY32837A (es) Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso

Legal Events

Date Code Title Description
FB Suspension of granting procedure